Xpert® Xpress CoV-2 plus (XPRS-COV2-10)
FDA 510(k) K242109 · Cepheid®
510(k) numberK242109
Submission
- Device name
- Xpert® Xpress CoV-2 plus (XPRS-COV2-10)
- Applicant
- Cepheid®
Sunnyvale, CA, US - Received
- July 19, 2024
- Decision date
- January 15, 2025
- Decision
- Substantially Equivalent (SESE)
- Type
- Dual Track 510(k)
- Summary
- 510(k) summary available from FDA
Device classification
- Product code
- QQX – Respiratory Specimen Nucleic Acid Sars-Cov-2 Test
- Device class
- Class II (moderate risk)
- Regulation
- 21 CFR 866.3981
- Specialty
- Microbiology
A device to detect and identify nucleic acid targets in respiratory specimens from SARS-CoV-2 that cause COVID-19 is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 nucleic acid targets in human clinical respiratory specimens from patients suspected of COVID-19 based on signs and symptoms of respiratory infections by their healthcare providers. The…
Other 510(k)s with product code QQX
| 510(k) | Device | Applicant | Decision |
|---|---|---|---|
| K243396 | Aptima SARS-CoV-2 AssayQQX · Traditional | Hologic, Inc. | 02/13/2025SE |
| K240867 | cobas® SARS-CoV-2 Qualitative for use on the cobas® 5800/6800/8800 SystemsQQX · Traditional | Roche Molecular Systems, Inc. | 02/11/2025SE |
| K241580 | Alinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m SARS-CoV-2 CTRL Kit (09N78-086)QQX · Traditional | Abbott Molecular | 12/06/2024SE |
| K233453 | Applied Biosystems TaqPath COVID-19 Diagnostic PCR KitQQX · Traditional | Life Technologies Corporation | 07/10/2024SE |
| K230440 | Xpert® Xpress CoV-2 plusQQX · Traditional | Cepheid® | 10/13/2023SE |
| K231306 | cobas SARS-CoV-2 Qualitative for use on the cobas 5800/6800/8800 SystemsQQX · Special | Roche Molecular Systems, Inc. | 06/01/2023SE |
| K213804 | cobas SARS-CoV-2 Qualitative for use on the cobas 6800/8800 SystemsQQX · Traditional | Roche Molecular Systems, Inc. | 10/22/2022SE |
| K212147 | Simplexa COVID-19 DirectQQX · Traditional | Diasorin Molecular, LLC | 09/13/2022SE |
| K221460 | BioFire COVID-19 Test 2QQX · Special | Biofire Defense, LLC | 07/25/2022SE |
| K211079 | BioFire COVID-19 Test 2QQX · Traditional | Biofire Defense, LLC | 11/01/2021SE |
More from Biofire Defense, LLC
| 510(k) | Device | Decision |
|---|---|---|
| K261362 | Xpert Hemorrhagic FeverQVR · Dual Track | 08/07/2026SE |
| K261867 | Xpert Carba-RPOC · Special | 07/02/2026SE |
| K253653 | Xpert Hemorrhagic Fever · Traditional | 02/20/2026SE |
| K251721 | Xpert GI PanelPCH · Traditional | 01/16/2026SE |
| K250996 | Xpert Xpress CoV-2/Flu/RSV plusQOF · Special | 05/01/2025SE |
| K250995 | Xpert Xpress CoV-2/Flu/RSV plusQOF · Special | 05/01/2025SE |
| K243730 | Xpert C. difficile/EpiOZN · Traditional | 02/28/2025SE |
| K250218 | Xpert® FII & FVNPR · Special | 02/21/2025SE |
| K242071 | Xpert Xpress CoV-2/Flu/RSV plusQOF · Dual Track | 01/10/2025SE |
| K243625 | Xpert MRSA/SA SSTINQX · Special | 12/18/2024SE |
Questions and answers
When was Xpert® Xpress CoV-2 plus (XPRS-COV2-10) cleared by the FDA?
Xpert® Xpress CoV-2 plus (XPRS-COV2-10) (K242109) received a 510(k) decision of Substantially Equivalent on January 15, 2025, 180 days after the submission was received.
What is the product code of K242109?
The FDA product code is QQX – Respiratory Specimen Nucleic Acid Sars-Cov-2 Test, a Class II (moderate risk) device regulated under 21 CFR 866.3981.